IASO BIOTHERAPEUTICS
IASO Biotherapeutics (IASO BIO) is a Nanjing-based biopharmaceutical company focused on the discovery, development and commercialization of cell therapies in the field of oncology.
IASO BIOTHERAPEUTICS
Industry:
Biotechnology Pharmaceutical
Founded:
2017-01-01
Address:
Nanjing, Jiangsu, China
Country:
China
Website Url:
http://www.iasobio.com
Total Employee:
251+
Status:
Active
Contact:
025-58287610
Email Addresses:
[email protected]
Total Funding:
168 M USD
Technology used in webpage:
SPF Apache Euro Microsoft Azure DNS PHP Apache 2.4 OpenSSL GlobalSign HiChina DNS Win32 Header
Similar Organizations
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Dunad Therapeutics
Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted protein degradation therapies.
Immutep
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.
MRM Health NV
MRM Health NV is a biopharmaceutical company focused on the discovery and development of therapeutics based on the human microbiome.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Sirnaomics
Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference technology.
WeHand
WeHand is a biopharmaceutical company focusing on the development of hypoglycemic drugs.
Current Employees Featured
Founder
Investors List
Co-Stone Venture Capital
Co-Stone Venture Capital investment in Series C - IASO Biotherapeutics
Everbright
Everbright investment in Series C - IASO Biotherapeutics
CCB International
CCB International investment in Series C - IASO Biotherapeutics
Plaisance Capital
Plaisance Capital investment in Series C - IASO Biotherapeutics
CDH Investments
CDH Investments investment in Series C - IASO Biotherapeutics
GL Ventures
GL Ventures investment in Series C - IASO Biotherapeutics
CNCB Capital
CNCB Capital investment in Series C - IASO Biotherapeutics
Hillhouse Capital Group
Hillhouse Capital Group investment in Series B - IASO Biotherapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2021-10-19 | IASO Bio Appoints Industry Veteran Dr. Alan Fu Chief Financial Officer |
Official Site Inspections
http://www.iasobio.com
- Host name: 120.133.2.80
- IP address: 120.133.2.80
- Location: China
- Latitude: 34.7725
- Longitude: 113.7266
- Timezone: Asia/Shanghai
More informations about "IASO Biotherapeutics"
Overview / ABOUT IASO / IASO，IASO Bio，IASO …
IASO，IASO Bio，IASO Biotherapeutics，IASO Biopharma，CT103A， CAR-T， cell therapy，dual-targeted CAR-TSee details»
IASO BioTherapeutics（驯鹿生物） - LinkedIn
IASO BioTherapeutics（驯鹿生物） | 1,638 followers on LinkedIn. Transforming innovation into life-changing therapies | IASO Bio is a clinical-stage biopharmaceutical company engaged in the ...See details»
IASO Biotherapeutics - Crunchbase Company Profile
IASO Biotherapeutics may be growing as it has recently achieved a significant regulatory milestone and secured substantial venture funding. The company, …See details»
Nanjing IASO Biotherapeutics Co., Ltd. - Drug pipelines ... - Patsnap
Cn.iasobio.com. Startups | Holding Company | Subsidiary Company | 2017 | Jiangsu Sheng, China | 100-250 | cn.iasobio.com. Last update 08 Mar 2025. Overview. Pipeline. ... The statistics for …See details»
Next Generation Vaccines - Iaso Therapeutics
Iaso’s initial product offering is a disruptive new virus-like particle, mutant Qβ, that shows superiority in generating antibodies of interest when compared to conjugate carrier proteins like Keyhole Limpet Hemocyanin, diphtheria toxoid, …See details»
IASO Biotherapeutics - Overview, News & Similar companies
Apr 3, 2024 IASO Biotherapeutics contact info: Phone number: +86 2558287610 Website: www.iasobio.com What does IASO Biotherapeutics do? Founded in 2017, IASO BIO is a …See details»
IASO BIO - 2025 Company Profile, Funding & Competitors - Tracxn
4 days ago IASO BIO has raised a total funding of $178M over 3 rounds. Its first funding round was on Mar 23, 2020. Its latest funding round was a Series C round on Jan 18, 2023 for an …See details»
驯鹿生物
驯鹿生物，驯鹿医药，驯鹿医疗，驯鹿技术，驯鹿科技，上海驯鹿，南京驯鹿，IASO BIO，IASO Biothrapeutics，驯鹿CAR-T细胞治疗，多发性骨髓瘤CAR-T，全人源双靶点CAR-TSee details»
IASO Bio 2025 Company Profile: Valuation, Funding
IASO Bio General Information Description. Developer of cellular innovative drugs designed for cancer biotherapeutics. The company's cell-therapy products aim to treat symptoms of hematological tumors, solid tumors and virus associated …See details»
Nanjing IASO Biotherapeutics Co., Ltd. - synapse.zhihuiya.com
4 days ago 了解Nanjing IASO Biotherapeutics Co., Ltd. (南京驯鹿生物技术股份有限公司)公司的药物管线，治疗领域，技术平台，以及它的23项临床试验, 798篇新闻和7篇文献，疾病领域:肿 …See details»
IASO Biotherapeutics Secures $108 Million Series C Funding to …
September 16, 2021, PLEASANTON, Calif. & NANJING, SHANGHAI, China – IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company focusing on …See details»
IASO Biotherapeutics - VentureRadar
Dansk Biotek Unknown n/a DANISH BIOTECH is a trade organization for Danish biotech companies with the aim to promote opportunities for biotechnology research, development and …See details»
Management Team / ABOUT IASO / IASO，IASO Bio，IASO …
IASO，IASO Bio，IASO Biotherapeutics，IASO Biopharma，CT103A， CAR-T， cell therapy，dual-targeted CAR-TSee details»
IASO Bio and Innovent Enhance Strategic Collaboration in Cell …
Jul 5, 2024 NANJING, SHANGHAI, CHINA, and SAN JOSE, CA., U.S., July 5, 2024 – IASO Biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, …See details»
Growth & Development / CAREERS / IASO，IASO Bio，IASO …
We believe that both professionals and leaders play a vital role in driving business development, therefore, IASO offers dual career path of Professional and Management opportunities for …See details»
IASO BIO Announces New Development Partnership with Umoja …
SAN JOSE, CALIFORNIA, SHANGHAI, NANJING, CHINA, AND SEATTLE, WASHINGTON, January 03, 2024 –IASO Biotherapeutics (“IASO Bio”), a biopharmaceutical company engaged …See details»
IASO BIO Announces New Development Partnership with Umoja …
Jan 4, 2024 SAN JOSE, CALIFORNIA, SHANGHAI, NANJING, CHINA, AND SEATTLE, WASHINGTON, January 04, 2024 –IASO Biotherapeutics (“IASO Bio”), a biopharmaceutical …See details»
IASO，IASO Bio，IASO Biotherapeutics，IASO …
IASO，IASO Bio，IASO Biotherapeutics，IASO Biopharma，CT103A， CAR-T， cell therapy，dual-targeted CAR-TSee details»
IASO Bio Receives FDA Approval of IND Application for IASO-782 …
Jun 16, 2023 The second product of IASO to receive IND approval from the FDA . SHANGHAI, NANJING, CHINA, AND SAN JOSE , Calif., June 16, 2023 - IASO Biotechnology (“IASO Bio”), …See details»
Management Team / ABOUT IASO / IASO，IASO Bio，IASO …
Dr. Jie Chen is the Chief Medical Officer at IASO Bio. He has 14 years of experience as an oncologist and over 20 years in the industry. Before joining IASO Bio, Dr. Chen was the Chief …See details»